Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma

21Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Cross-reactive epitopes (CREs) are similar epitopes on viruses that are recognized or neutralized by same antibodies. The S protein of SARS-CoV-2, similar to type I fusion proteins of viruses such as HIV-1 envelope (Env) and influenza hemagglutinin, is heavily glycosylated. Viral Env glycans, though host derived, are distinctly processed and thereby recognized or accommodated during antibody responses. In recent years, highly potent and/or broadly neutralizing human monoclonal antibodies (bnAbs) that are generated in chronic HIV-1 infections have been defined. These bnAbs exhibit atypical features such as extensive somatic hypermutations, long complementary determining region (CDR) lengths, tyrosine sulfation and presence of insertions/deletions, enabling them to effectively neutralize diverse HIV-1 viruses despite extensive variations within the core epitopes they recognize. As some of the HIV-1 bnAbs have evolved to recognize the dense viral glycans and crossreactive epitopes (CREs), we assessed if these bnAbs cross-react with SARS-CoV-2. Several HIV-1 bnAbs showed cross-reactivity with SARS-CoV-2 while one HIV-1 CD4 binding site bnAb, N6, neutralized SARS-CoV-2. Furthermore, neutralizing plasma antibodies of chronically HIV-1 infected children showed cross neutralizing activity against SARS-CoV-2 pseudoviruses. Collectively, our observations suggest that human monoclonal antibodies tolerating extensive epitope variability can be leveraged to neutralize pathogens with related antigenic profile. Copyright:

References Powered by Scopus

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

14658Citations
N/AReaders
Get full text

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

6488Citations
N/AReaders
Get full text

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

1335Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Monoclonal antibody therapies against SARS-CoV-2

159Citations
N/AReaders
Get full text

Overview of neutralizing antibodies and their potential in COVID-19

52Citations
N/AReaders
Get full text

Diagnostics and analysis of SARS-CoV-2: current status, recent advances, challenges and perspectives

29Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Mishra, N., Kumar, S., Singh, S., Bansal, T., Jain, N., Saluja, S., … Luthra, K. (2021). Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma. PLoS Pathogens, 17(9). https://doi.org/10.1371/journal.ppat.1009958

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 13

57%

Researcher 9

39%

Professor / Associate Prof. 1

4%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 6

40%

Nursing and Health Professions 3

20%

Medicine and Dentistry 3

20%

Immunology and Microbiology 3

20%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 40

Save time finding and organizing research with Mendeley

Sign up for free